FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers

March 27, 2017 – The U.S. Food and Drug Administration today approved niraparib for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. “Maintenance therapy is an important part of a cancer treatment regimen for patients … (leggi tutto)